Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia

International Journal of Antimicrobial Agents

Volumn 43, Issue 4, 2014, Pages 378-382

  Khawcharoenporn, Thana ^a   Pruetpongpun, Nattapol ^a   Tiamsak, Pimsiri ^b   Rutchanawech, Sasinuch ^a   Mundy, Linda M ^c   Apisarnthanarak, Anucha ^a  

^a THAMMASAT UNIVERSITY   (Thailand)

^b THAMMASAT UNIVERSITY   (Thailand)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Acinetobacter baumannii; Colistin; Extensively drug resistant; Outcomes; Pneumonia; Treatment

Indexed keywords

CEFOPERAZONE PLUS SULBACTAM; COLISTIMETHATE; DORIPENEM; IMIPENEM; MEROPENEM; SULTAMICILLIN; TIGECYCLINE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; COLISTIN; MINOCYCLINE; SULBACTAM;

ACINETOBACTER INFECTION; ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGED; APACHE; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT ACINETOBACTER BAUMANNII PNEUMONIA; FEMALE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INTENSIVE CARE; LENGTH OF STAY; LOADING DRUG DOSE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NEUROTOXICITY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TIME TO TREATMENT; VENTILATOR ASSOCIATED PNEUMONIA; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANALOGS AND DERIVATIVES; DRUG COMBINATION; DRUG EFFECTS; INTENSIVE CARE UNIT; MICROBIOLOGY; MIDDLE AGED; MORTALITY; MULTIDRUG RESISTANCE; PATHOGENICITY; PNEUMONIA, VENTILATOR-ASSOCIATED; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; APACHE; CARBAPENEMS; COHORT STUDIES; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MIDDLE AGED; MINOCYCLINE; PNEUMONIA, VENTILATOR-ASSOCIATED; RETROSPECTIVE STUDIES; SULBACTAM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84898007596     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.01.016     Document Type: Article

References (15)

1. A. Apisarnthanarak, L.Y. Hsu, T. Khawcharoenporn, and L.M. Mundy Carbapenem-resistant Gram-negative bacteria: how to prioritize infection prevention and control interventions in resource-limited settings? Expert Rev Anti Infect Ther 11 2013 147 157
2. J. Garnacho-Montero, C. Ortiz-Leyba, F.J. Jiménez-Jiménez, A.E. Barrero-Almodóvar, J.L. García-Garmendia, and.M. Bernabeu-WittelI Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP Clin Infect Dis 36 2003 1111 1118
3. G. Kalin, E. Alp, R. Coskun, H. Demiraslan, K. Gündogan, and M. Doganay Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment? J Infect Chemother 18 2012 872 877
4. E. Durante-Mangoni, G. Signoriello, R. Andini, A. Mattei, M. De Cristoforo, and P. Murino et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial Clin Infect Dis 57 2013 349 358
5. Y.T. Lee, S.C. Kuo, S.P. Yang, Y.T. Lin, D.H. Chiang, and F.C. Tseng et al. Bacteremic nosocomial pneumonia caused by Acinetobacter baumannii and Acinetobacter nosocomialis: a single or two distinct clinical entities? Clin Microbiol Infect 19 2013 640 645
6. A.L. Kwa, C. Loh, J.G. Low, A. Kurup, and V.H. Tam Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa Clin Infect Dis 41 2005 754 757
7. E. Mutlu Yilmaz, M. Sunbul, A. Aksoy, H. Yilmaz, A.K. Guney, and T. Guvenc Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii Int J Antimicrob Agents 40 2012 332 336
8. M.E. Pachón-Ibáñez, F. Docobo-Pérez, R. López-Rojas, J. Domínguez-Herrera, M.E. Jiménez-Mejias, and A. García-Curiel et al. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii Antimicrob Agents Chemother 54 2010 1165 1172
9. P. Pongpech, S. Amornnopparattanakul, S. Panapakdee, S. Fungwithaya, P. Nannha, and C. Dhiraputra et al. Antibacterial activity of carbapenem-based combinations against multidrug-resistant Acinetobacter baumannii J Med Assoc Thai 93 2010 161 171
10. R.N. Jones, M.J. Ferraro, L.B. Reller, P.C. Schreckenberger, J.M. Swenson, and H.S. Sader Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp J Clin Microbiol 45 2007 227 230
11. American Thoracic Society; Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia Am J Respir Crit Care Med 171 2005 388 416
12. S.M. Garonzik, J. Li, V. Thamlikitkul, D.L. Paterson, S. Shoham, and J. Jacob et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients Antimicrob Agents Chemother 55 2011 3284 3294
13. S. Esposito, and S. Leone Antimicrobial treatment for intensive care unit (ICU) infections including the role of the infectious disease specialist Int J Antimicrob Agents 29 2007 494 500
14. S. Anunnatsiri, and P. Tonsawan Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand Southeast Asian J Trop Med Public Health 42 2011 693 703
15. M.J. Sarnak, and B.L. Jaber Mortality caused by sepsis in patients with end-stage renal disease compared with the general population Kidney Int 58 2000 1758 1764